Clinical Commander

Back to dossier
cardio.acute-hf.checkpoint-inhibitor-cardiotoxicity.v1PRODUCTION
cardio.acute-hf.checkpoint-inhibitor-cardiotoxicity.v1

Acute HF — Immune checkpoint inhibitor (ICI) cardiotoxicity / fulminant myocarditis

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

ICI cardiotoxicity = T-cell-mediated myocarditis from PD-1/PD-L1/CTLA-4 inhibitor; HIGHEST mortality of all irAEs; peak 4-6 wk post-initiation; combination ICI worse than monotherapy; treat empirically with high-dose steroid while workup proceeds (delay = death)

Inputs
2
Actions
0
Advance rule
Set
Advance when

ICI cardiotoxicity suspicion confirmed

Patient inputs (13)

Age informs immunosuppression tolerance + cancer-therapy continuation calculus

Cancer prognosis informs immunosuppression intensity + ICI permanent discontinuation impact

Specific ICI (PD-1 vs PD-L1 vs CTLA-4) + monotherapy vs combination (combination ICI carries higher myocarditis incidence + severity); cycle number; date of last dose

eGFR for cardiac MRI gadolinium dosing + ACEi/ARB/ARNI dosing + immunosuppression considerations

High-sensitivity troponin is the most sensitive ICI myocarditis screen; often markedly elevated (>100x ULN); serial trending guides treatment response (Mahmood JACC 2018 PMID 29420041)

CK total + CK-MB to detect concomitant myositis (combined irAE; very common in ICI myocarditis); LDH also useful

NT-proBNP elevation suggests cardiac strain; baseline + serial for response tracking

ECG: new AV block (1st/2nd/3rd-degree), QRS widening, ventricular ectopy, or new ventricular arrhythmia — characteristic and ominous in ICI myocarditis

Echo for LVEF + GLS strain + RV function; LVEF may be preserved early in ICI myocarditis (troponin precedes LVEF drop)

SBP guides shock recognition + immunosuppression adjuncts + MCS decision

Cardiac MRI with T1/T2 mapping + LGE per Lake Louise criteria — high diagnostic yield for ICI myocarditis when EMB not feasible

EMB is the GOLD STANDARD: T-cell-predominant lymphocytic infiltrate confirms ICI myocarditis; reserve for life-threatening cases or diagnostic uncertainty after MRI

Concomitant myositis, myasthenia gravis, hepatitis, or thyroiditis often co-occurs with ICI myocarditis; combined irAE pattern significantly worsens prognosis

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningfulminant_ici_myocarditis_with_storm
    ICI patient with troponin elevation + LVEF drop OR high-grade AV block OR ventricular arrhythmia OR cardiogenic shock — fulminant ICI myocarditis storm requiring abatacept escalation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningici_rechallenge_attempt_after_grade_3_or_4_myocarditis
    ICI patient post-recovery from grade 3-4 myocarditis with rechallenge attempt — CONTRAINDICATED per Power PMID 33779739 (recurrent myocarditis ≥50%)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningrefractory_ici_myocarditis_storm_requiring_abatacept_escalation
    Persistent troponin elevation or LVEF drop after 24-72h of high-dose methylprednisolone — steroid-refractory ICI myocarditis demanding abatacept salvage
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcardiogenic_shock_progression_in_ici_myocarditis
    Fulminant ICI myocarditis progressing to SCAI C+ cardiogenic shock — VA-ECMO bridge consideration
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereinfliximab_inadvertent_administration_in_ici_myocarditis_with_hf
    Inadvertent infliximab administration in patient with ICI myocarditis and reduced LVEF — TNF-α inhibitor worsens cardiac HF
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

ICI myocarditis storm protocol — high-dose steroid first-line, abatacept salvage, infliximab CONTRAINDICATED for cardiac, plus standard ADHF backbone
axis: ici_myocarditis_storm_phenotype
Selected axis "ICI myocarditis storm protocol — high-dose steroid first-line, abatacept salvage, infliximab CONTRAINDICATED for cardiac, plus standard ADHF backbone" by default fallback (first axis)
  • methylprednisolone
    first line
    systemic_corticosteroid
    1 g IV daily ×3-5 d then prednisone 1 mg/kg PO taper • IV • daily
    triggers: ici_myocarditis_grade_2_or_higher, troponin_elevation_in_ici_patient
    Mahmood JACC 2018 PMID 29420041 — high-dose steroid is FIRST-LINE; treat empirically; delay = death; ESMO + NCCN + AHA 2022 cardio-onc
    rxcui 6902
  • abatacept
    second line
    ctla4_ig_immunomodulator
    10 mg/kg IV q2 weeks (5 doses) • IV • q2 weeks
    triggers: ici_myocarditis_steroid_refractory_at_24_to_72h
    Salem RIVAL PMID 39432268 — abatacept (CTLA-4 Ig) reduces 90-day mortality in steroid-refractory ICI myocarditis; preferred salvage over infliximab in HF
    rxcui 614391
  • mycophenolate mofetil
    second line
    antimetabolite_immunosuppressant
    1 g PO BID • PO • BID
    triggers: ici_myocarditis_steroid_refractory_or_steroid_sparing_needed
    Steroid-sparing immunosuppressant in refractory ICI myocarditis; ESMO + NCCN guidelines support
    rxcui 68149
  • IVIG (immunoglobulin G)
    second line
    immunomodulator_pooled_ig
    2 g/kg IV divided over 2-5 days • IV • as scheduled
    triggers: ici_myocarditis_refractory_or_combined_irae
    Refractory ICI myocarditis salvage; useful when concomitant myasthenia gravis or other irAE present
    rxcui 5666
  • infliximab
    rescue
    tnf_alpha_inhibitor
    CONTRAINDICATED for cardiac ICI myocarditis • IV • do_not_use
    triggers: contraindicated_in_ici_cardiotoxicity_with_hf
    TNF-α inhibitor worsens cardiac HF; CONTRAINDICATED for ICI myocarditis with HF or LVEF reduction; abatacept preferred salvage; only consider for non-cardiac irAE if no HF
    rxcui 191831
  • furosemide
    first line
    loop_diuretic
    40-80 mg IV bolus then 5-10 mg/h infusion • IV • as scheduled
    triggers: ici_myocarditis_with_pulmonary_edema
    Standard ADHF diuresis; DOSE PMID 21366472
    rxcui 4603
  • norepinephrine
    first line
    vasopressor_alpha_beta
    0.05-0.5 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: ici_myocarditis_with_cardiogenic_shock
    SOAP-II PMID 20200382 — first vasopressor in cardiogenic shock
    rxcui 7512
  • carvedilol
    first line
    beta_alpha_blocker
    3.125 mg PO BID titrate • PO • BID
    triggers: ici_myocarditis_recovered_lvef_below_40_stable
    GDMT once stable; CAPRICORN PMID 11356436; ESC cardio-onc 2022 PMID 36017575
    rxcui 20352
  • sacubitril-valsartan
    first line
    arni
    24/26 mg PO BID titrate • PO • BID
    triggers: ici_myocarditis_recovered_lvef_below_40_acei_intolerant_or_de_novo_hf
    PIONEER-HF PMID 30403955; ESC cardio-onc 2022 Class IIa
    rxcui 1656328
  • spironolactone
    first line
    mra
    12.5-25 mg PO daily • PO • daily
    triggers: ici_myocarditis_recovered_lvef_below_40_k_below_5_egfr_above_30
    RALES PMID 10471456; ESC cardio-onc 2022 Class I
    rxcui 9997
  • empagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: ici_myocarditis_recovered_lvef_below_40_egfr_above_20
    EMPULSE PMID 35347356; ESC cardio-onc 2022 Class IIa
    rxcui 1545653

outpatient playbook — drug actions (1)

  1. 1. continue 4-pillar GDMT until LVEF normalized + stable ≥6-12 mo (avoid TRED-HF withdrawal harm)
    rxcui 1656328
    ARNI + BB + MRA + SGLT2i at max tolerated • PO • as scheduled
    trigger: Persistent HFrEF
    TRED-HF PMID 30429051; ESC cardio-onc 2022

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Patient on active PD-1/PD-L1/CTLA-4 inhibitor (nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, avelumab, cemiplimab) presenting with new dyspnea, chest pain, palpitations, or syncope — ICI myocarditis until proven otherwise; Any troponin elevation in an ICI patient — STAT cardiology consult; treat empirically with high-dose methylprednisolone while workup proceeds (Mahmood JACC 2018 PMID 29420041 — delay = death); New high-grade AV block, ventricular arrhythmia, or QRS widening in ICI patient (4-6 wk post-initiation peak) — fulminant ICI myocarditis pattern.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — Immune checkpoint inhibitor (ICI) cardiotoxicity / fulminant myocarditis** (cardio.acute-hf.checkpoint-inhibitor-cardiotoxicity.v1).
Scope: ICI cardiotoxicity = T-cell-mediated myocarditis from PD-1/PD-L1/CTLA-4 inhibitor; HIGHEST mortality of all irAEs; peak 4-6 wk post-initiation; combination ICI worse than monotherapy; treat empirically with high-dose steroid while workup proceeds (delay = death)

No severity triggers fired against current inputs.

Plan

Regimen axis: **ICI myocarditis storm protocol — high-dose steroid first-line, abatacept salvage, infliximab CONTRAINDICATED for cardiac, plus standard ADHF backbone**.
1. methylprednisolone 1 g IV daily ×3-5 d then prednisone 1 mg/kg PO taper IV daily (systemic_corticosteroid, first line) — Mahmood JACC 2018 PMID 29420041 — high-dose steroid is FIRST-LINE; treat empirically; delay = death; ESMO + NCCN + AHA 2022 cardio-onc
2. abatacept 10 mg/kg IV q2 weeks (5 doses) IV q2 weeks (ctla4_ig_immunomodulator, second line) — Salem RIVAL PMID 39432268 — abatacept (CTLA-4 Ig) reduces 90-day mortality in steroid-refractory ICI myocarditis; preferred salvage over infliximab in HF
3. mycophenolate mofetil 1 g PO BID PO BID (antimetabolite_immunosuppressant, second line) — Steroid-sparing immunosuppressant in refractory ICI myocarditis; ESMO + NCCN guidelines support
4. IVIG (immunoglobulin G) 2 g/kg IV divided over 2-5 days IV as scheduled (immunomodulator_pooled_ig, second line) — Refractory ICI myocarditis salvage; useful when concomitant myasthenia gravis or other irAE present
5. infliximab CONTRAINDICATED for cardiac ICI myocarditis IV do_not_use (tnf_alpha_inhibitor, rescue) — TNF-α inhibitor worsens cardiac HF; CONTRAINDICATED for ICI myocarditis with HF or LVEF reduction; abatacept preferred salvage; only consider for non-cardiac irAE if no HF
6. furosemide 40-80 mg IV bolus then 5-10 mg/h infusion IV as scheduled (loop_diuretic, first line) — Standard ADHF diuresis; DOSE PMID 21366472
7. norepinephrine 0.05-0.5 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor_alpha_beta, first line) — SOAP-II PMID 20200382 — first vasopressor in cardiogenic shock
8. carvedilol 3.125 mg PO BID titrate PO BID (beta_alpha_blocker, first line) — GDMT once stable; CAPRICORN PMID 11356436; ESC cardio-onc 2022 PMID 36017575
9. sacubitril-valsartan 24/26 mg PO BID titrate PO BID (arni, first line) — PIONEER-HF PMID 30403955; ESC cardio-onc 2022 Class IIa
10. spironolactone 12.5-25 mg PO daily PO daily (mra, first line) — RALES PMID 10471456; ESC cardio-onc 2022 Class I
11. empagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, first line) — EMPULSE PMID 35347356; ESC cardio-onc 2022 Class IIa

Setting playbook (outpatient) — Long-term cardio-oncology surveillance: serial echo with strain at 3, 6, 12 months; troponin at each visit; ICD evaluation if persistent LVEF <35% on full GDMT; permanent ICI hold maintained; alternative non-ICI cancer therapy coordination; mental health follow-up
12. continue 4-pillar GDMT until LVEF normalized + stable ≥6-12 mo (avoid TRED-HF withdrawal harm) ARNI + BB + MRA + SGLT2i at max tolerated PO as scheduled — Persistent HFrEF (TRED-HF PMID 30429051; ESC cardio-onc 2022)

Non-pharmacologic actions:
- Cardio-oncology clinic q3-6 mo
- Survivorship clinic annual
- Cardiac rehab maintenance
- ICD evaluation if LVEF <35% at 3-6 mo on full GDMT
- Permanent ICI hold maintained
- Alternative non-ICI cancer therapy maintenance with oncology
- Mental health screen (PTSD post-fulminant illness common)

AVOID / contraindication checks:
- Start_methylprednisolone_empirically_for_suspected_ici_myocarditis_within_24h (delay = death; Mahmood PMID 29420041)
- Hold_ici_permanently_for_grade_3_or_4_myocarditis (rechallenge → recurrent myocarditis ≥50% per Power PMID 33779739)
- Avoid_infliximab_in_ici_myocarditis_with_hf (TNF α inhibitor worsens cardiac HF; abatacept preferred salvage)
- Taper_steroid_slowly_over_4_to_6_weeks_after_ici_myocarditis (rebound myocarditis risk if rapid taper)
- Add_pjp_prophylaxis_with_long_term_steroid_above_20mg_prednisone_4_weeks (TMP SMX or atovaquone)
- Add_ppi_or_h2_blocker_with_high_dose_steroid (GI prophylaxis)
- Monitor_glucose_q6h_during_high_dose_steroid (steroid induced hyperglycemia)
- Abatacept_screen_for_latent_tb_before_initiation (CTLA 4 Ig immunosuppression)
- Pacer_pads_at_bedside_for_high_grade_block_in_ici_myocarditis (sudden complete heart block risk)
- Joint_cardio_onc_decision_for_alternative_non_ici_cancer_therapy (ICI permanently held)

Monitoring

Regimen monitoring:
- continuous telemetry with pacer pads for block and vt (high-grade AV block characteristic + ominous in ICI myocarditis)
- serial high sensitivity troponin q6h until trending down (treatment response marker)
- daily nt probnp and lvef with strain for response tracking
- daily lfts for concomitant hepatitis irae (combined irAE common)
- daily ck for concomitant myositis irae (combined irAE common)
- tsh for concomitant thyroiditis irae at baseline and serial
- q6h glucose during high dose steroid phase (hyperglycemia)
- cardiac mri at 6 weeks for treatment response if no emb
- monthly echo for first 6 months then quarterly

Setting (outpatient) monitoring:
- Quarterly clinic visits + echo
- Annual NT-proBNP + troponin
- Cancer surveillance per oncology

Follow-up plan: Cardio-oncology clinic at 2 weeks, 6 weeks, 3 months, 6 months, 12 months; serial troponin + echo + MRI for surveillance; permanent ICI hold (rechallenge contraindicated per Power PMID 33779739); shared decision on alternative non-ICI cancer therapy with oncology; ICD evaluation if persistent LVEF <35% on full GDMT; long-term steroid taper monitoring
- Close-out criterion: cardio-oncology + permanent ICI-hold + alternative-therapy + survivorship plan documented

Monitoring phase: Continuous telemetry with pacer pads (block + VT/VF surveillance), serial troponin q6h until trending down, daily NT-proBNP, daily echo, daily BMP, daily LFTs (steroid + concomitant hepatitis irAE), daily glucose (steroid hyperglycemia), repeat MRI at 6 weeks for response if EMB not done

Disposition

Current setting: outpatient — Long-term cardio-oncology surveillance: serial echo with strain at 3, 6, 12 months; troponin at each visit; ICD evaluation if persistent LVEF <35% on full GDMT; permanent ICI hold maintained; alternative non-ICI cancer therapy coordination; mental health follow-up

Disposition criteria:
- Long-term continuation; cross-link to cardio.hfref.core.v1 if HFrEF persists past 12 mo; survivorship lifelong with permanent ICI-hold flag

Escalation triggers (move to higher acuity):
- Worsening LVEF despite GDMT → advanced HF + transplant evaluation (cancer disease-free interval matters)
- Recurrent troponin or new myocarditis features → admit + restart steroid + abatacept
- Cancer progression requiring restart of cardiotoxic agent → joint cardio + onc + ethics decision (ICI rechallenge contraindicated)
- ICD therapy delivered → urgent EP

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] ICI patient with troponin elevation + LVEF drop OR high-grade AV block OR ventricular arrhythmia OR cardiogenic shock — fulminant ICI myocarditis storm requiring abatacept escalation
- [LIFE_THREATENING] ICI patient post-recovery from grade 3-4 myocarditis with rechallenge attempt — CONTRAINDICATED per Power PMID 33779739 (recurrent myocarditis ≥50%)
- [LIFE_THREATENING] Persistent troponin elevation or LVEF drop after 24-72h of high-dose methylprednisolone — steroid-refractory ICI myocarditis demanding abatacept salvage

Citations

- ESC cardio-oncology 2022 + Mahmood ICI myocarditis JACC 2018 + AHA cardio-oncology 2022 + Salem RIVAL abatacept refractory ICI myocarditis [PMID:36017575](https://pubmed.ncbi.nlm.nih.gov/36017575/)
- Cited evidence (PMID 29420041) [PMID:29420041](https://pubmed.ncbi.nlm.nih.gov/29420041/)
- Cited evidence (PMID 30184457) [PMID:30184457](https://pubmed.ncbi.nlm.nih.gov/30184457/)
- Cited evidence (PMID 35403432) [PMID:35403432](https://pubmed.ncbi.nlm.nih.gov/35403432/)
- Cited evidence (PMID 33779739) [PMID:33779739](https://pubmed.ncbi.nlm.nih.gov/33779739/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ESC cardio-oncology 2022 + Mahmood ICI myocarditis JACC 2018 + AHA cardio-oncology 2022 + Salem RIVAL abatacept refractory ICI myocarditis — PMID:36017575
  • Cited evidence (PMID 29420041) — PMID:29420041
  • Cited evidence (PMID 30184457) — PMID:30184457
  • Cited evidence (PMID 35403432) — PMID:35403432
  • Cited evidence (PMID 33779739) — PMID:33779739